Challenges in developing Geroscience trials

Yves Rolland; Felipe Sierra; Luigi Ferrucci; Nir Barzilai; Rafael De Cabo; Joan Mannick; Anthony Oliva; William Evans; Davide Angioni; Philipe De Souto Barreto; Jeremy Raffin; Bruno Vellas; James L. Kirkland; Sandrine Andrieu; Daniel Bacqueville; Heike Bischoff-Ferrari; Guillaume Blivet; Timothy Cash; Ana Maria Cuervo; Noelie Davezac; Andrea Dimet-Wiley; Alexander Fleming; Friedlander Gérard; Mitzi Gonzales; Sophie Guyonnet; Joshua Hare; Suzanne Hendrix; Christian Jorgensen; Matt Kaeberlein; Mehmood Khan; Stephen Kritchevsky; Aksana Labokha; Olivier Lairez; Stephanie Lederman; Jean Mariani; Lefkos Middleton; John Newman; Angelo Parini; Susan Peschin; Marco Prunotto; Sami Sagol; Suzanne Tomlinson; Georg Terstappen; Jacques Touchon; Cendrine Tourette; Rob Van Maanen; Eric Verdin; Stan Watowich; Lei Zhang; Alex Zhavoronkov

doi:10.1038/s41467-023-39786-7

Challenges in developing Geroscience trials

Yves Rolland
, Felipe Sierra
, Luigi Ferrucci
, Nir Barzilai
, Rafael De Cabo
, Joan Mannick
, Anthony Oliva
, William Evans
, Davide Angioni
, Philipe De Souto Barreto
, Jeremy Raffin
, Bruno Vellas
, James L. Kirkland
, Sandrine Andrieu
, Daniel Bacqueville
, Heike Bischoff-Ferrari
, Guillaume Blivet
, Timothy Cash
, Ana Maria Cuervo
, Noelie Davezac

Andrea Dimet-Wiley, Alexander Fleming, Friedlander Gérard, Mitzi Gonzales, Sophie Guyonnet, Joshua Hare, Suzanne Hendrix, Christian Jorgensen, Matt Kaeberlein, Mehmood Khan, Stephen Kritchevsky, Aksana Labokha, Olivier Lairez, Stephanie Lederman, Jean Mariani, Lefkos Middleton, John Newman, Angelo Parini, Susan Peschin, Marco Prunotto, Sami Sagol, Suzanne Tomlinson, Georg Terstappen, Jacques Touchon, Cendrine Tourette, Rob Van Maanen, Eric Verdin, Stan Watowich, Lei Zhang, Alex Zhavoronkov

Department of Neurology

Producción científica: Review article › revisión exhaustiva

63 Citas (Scopus)

Resumen

Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses (“Gerodiagnostics”). This article reports the main results of a Task Force of experts in Geroscience.

Idioma original	English (US)
Número de artículo	5038
Publicación	Nature communications
Volumen	14
N.º	1
DOI	https://doi.org/10.1038/s41467-023-39786-7
Estado	Published - dic 2023

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Acceder al documento

10.1038/s41467-023-39786-7

Otros archivos y enlaces

Citar esto

Rolland, Y., Sierra, F., Ferrucci, L., Barzilai, N., De Cabo, R., Mannick, J., Oliva, A., Evans, W., Angioni, D., De Souto Barreto, P., Raffin, J., Vellas, B., Kirkland, J. L., Andrieu, S., Bacqueville, D., Bischoff-Ferrari, H., Blivet, G., Cash, T., Cuervo, A. M., ... Zhavoronkov, A. (2023). Challenges in developing Geroscience trials. Nature communications, 14(1), Artículo 5038. https://doi.org/10.1038/s41467-023-39786-7

Rolland, Y, Sierra, F, Ferrucci, L, Barzilai, N, De Cabo, R, Mannick, J, Oliva, A, Evans, W, Angioni, D, De Souto Barreto, P, Raffin, J, Vellas, B, Kirkland, JL, Andrieu, S, Bacqueville, D, Bischoff-Ferrari, H, Blivet, G, Cash, T, Cuervo, AM, Davezac, N, Dimet-Wiley, A, Fleming, A, Gérard, F, Gonzales, M, Guyonnet, S, Hare, J, Hendrix, S, Jorgensen, C, Kaeberlein, M, Khan, M, Kritchevsky, S, Labokha, A, Lairez, O, Lederman, S, Mariani, J, Middleton, L, Newman, J, Parini, A, Peschin, S, Prunotto, M, Sagol, S, Tomlinson, S, Terstappen, G, Touchon, J, Tourette, C, Van Maanen, R, Verdin, E, Watowich, S, Zhang, L & Zhavoronkov, A 2023, 'Challenges in developing Geroscience trials', Nature communications, vol. 14, n.º 1, 5038. https://doi.org/10.1038/s41467-023-39786-7

@article{e70ce3e1e40c4f0f843388090c591fd0,

title = "Challenges in developing Geroscience trials",

abstract = "Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses (“Gerodiagnostics”). This article reports the main results of a Task Force of experts in Geroscience.",

author = "Yves Rolland and Felipe Sierra and Luigi Ferrucci and Nir Barzilai and \{De Cabo\}, Rafael and Joan Mannick and Anthony Oliva and William Evans and Davide Angioni and \{De Souto Barreto\}, Philipe and Jeremy Raffin and Bruno Vellas and Kirkland, \{James L.\} and Sandrine Andrieu and Daniel Bacqueville and Heike Bischoff-Ferrari and Guillaume Blivet and Timothy Cash and Cuervo, \{Ana Maria\} and Noelie Davezac and Andrea Dimet-Wiley and Alexander Fleming and Friedlander G{\'e}rard and Mitzi Gonzales and Sophie Guyonnet and Joshua Hare and Suzanne Hendrix and Christian Jorgensen and Matt Kaeberlein and Mehmood Khan and Stephen Kritchevsky and Aksana Labokha and Olivier Lairez and Stephanie Lederman and Jean Mariani and Lefkos Middleton and John Newman and Angelo Parini and Susan Peschin and Marco Prunotto and Sami Sagol and Suzanne Tomlinson and Georg Terstappen and Jacques Touchon and Cendrine Tourette and \{Van Maanen\}, Rob and Eric Verdin and Stan Watowich and Lei Zhang and Alex Zhavoronkov",

note = "Publisher Copyright: {\textcopyright} 2023, Springer Nature Limited.",

year = "2023",

month = dec,

doi = "10.1038/s41467-023-39786-7",

language = "English (US)",

volume = "14",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Challenges in developing Geroscience trials

AU - Rolland, Yves

AU - Sierra, Felipe

AU - Ferrucci, Luigi

AU - Barzilai, Nir

AU - De Cabo, Rafael

AU - Mannick, Joan

AU - Oliva, Anthony

AU - Evans, William

AU - Angioni, Davide

AU - De Souto Barreto, Philipe

AU - Raffin, Jeremy

AU - Vellas, Bruno

AU - Kirkland, James L.

AU - Andrieu, Sandrine

AU - Bacqueville, Daniel

AU - Bischoff-Ferrari, Heike

AU - Blivet, Guillaume

AU - Cash, Timothy

AU - Cuervo, Ana Maria

AU - Davezac, Noelie

AU - Dimet-Wiley, Andrea

AU - Fleming, Alexander

AU - Gérard, Friedlander

AU - Gonzales, Mitzi

AU - Guyonnet, Sophie

AU - Hare, Joshua

AU - Hendrix, Suzanne

AU - Jorgensen, Christian

AU - Kaeberlein, Matt

AU - Khan, Mehmood

AU - Kritchevsky, Stephen

AU - Labokha, Aksana

AU - Lairez, Olivier

AU - Lederman, Stephanie

AU - Mariani, Jean

AU - Middleton, Lefkos

AU - Newman, John

AU - Parini, Angelo

AU - Peschin, Susan

AU - Prunotto, Marco

AU - Sagol, Sami

AU - Tomlinson, Suzanne

AU - Terstappen, Georg

AU - Touchon, Jacques

AU - Tourette, Cendrine

AU - Van Maanen, Rob

AU - Verdin, Eric

AU - Watowich, Stan

AU - Zhang, Lei

AU - Zhavoronkov, Alex

PY - 2023/12

Y1 - 2023/12

N2 - Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses (“Gerodiagnostics”). This article reports the main results of a Task Force of experts in Geroscience.

AB - Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses (“Gerodiagnostics”). This article reports the main results of a Task Force of experts in Geroscience.

UR - https://www.scopus.com/pages/publications/85168324555

UR - https://www.scopus.com/pages/publications/85168324555#tab=citedBy

U2 - 10.1038/s41467-023-39786-7

DO - 10.1038/s41467-023-39786-7

M3 - Review article

C2 - 37598227

AN - SCOPUS:85168324555

SN - 2041-1723

VL - 14

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 5038

ER -

Challenges in developing Geroscience trials

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto